TMAO Lab Test: How to Interpret Your Result

What TMAO Is and Why It Matters for Women

TMAO stands for trimethylamine N-oxide. It is a small molecule your liver produces after gut bacteria convert choline, phosphatidylcholine (lecithin), and L-carnitine from food into trimethylamine (TMA), which the liver enzyme FMO3 then oxidizes into TMAO. The result enters your bloodstream, and research published in the New England Journal of Medicine first established in 2013 that plasma TMAO independently predicted major adverse cardiovascular events (MACE) in a cohort of 4,007 adults.

Why does this matter specifically to you as a woman? Because heart disease is still the leading cause of death in women in the United States, yet women are frequently under-represented in cardiovascular trials, and their risk can look different on standard panels. TMAO adds a layer of metabolic information that conventional lipid panels miss. It reflects your gut microbiome's composition, your dietary pattern, and your liver's FMO3 enzyme activity, all of which are influenced by your hormonal status.

How the Gut Microbiome Connects to Your Heart

Your gut bacteria are not passive bystanders. Specific genera, particularly Prevotella, Clostridium, and certain Firmicutes species, have a high capacity to convert dietary precursors into TMA. A gut microbiome dominated by these bacteria will produce more TMAO even if your diet is only moderately rich in choline or carnitine.

A landmark NEJM study by Tang and colleagues showed that TMAO levels above the upper quartile were associated with a hazard ratio of 2.54 for MACE over a three-year follow-up, after adjusting for traditional cardiovascular risk factors. That is a clinically meaningful signal.

FMO3 and Sex Differences in TMAO Metabolism

The liver enzyme FMO3 converts TMA to TMAO. Animal studies show that FMO3 expression is higher in female mice than in male mice, and estrogen appears to upregulate it. Preclinical data published in Nature Medicine suggest this means females may convert TMA to TMAO more efficiently than males at the enzymatic level. Whether this directly translates to higher steady-state TMAO in premenopausal women compared with age-matched men is still being clarified in humans, and this is an area where the evidence gap is real. Most large TMAO outcome studies have not reported sex-stratified FMO3 activity data. What is established is that hormonal transitions, particularly the drop in estrogen at menopause, can shift the gut microbiome toward a less diverse, more pro-inflammatory composition, and this shift may secondarily raise TMAO.

What Is a Normal TMAO Range?

Most clinical laboratories report TMAO in plasma micromolar (µM) concentrations after a 12-hour overnight fast. A commonly cited reference interval places the population median around 3.0 to 4.5 µM in fasting adults eating a mixed Western diet. Values below approximately 6.2 µM are generally considered within an acceptable range for cardiovascular risk stratification, though no single professional society has yet issued a standardized cut-off.

The Cleveland HeartLab, which was among the first to commercialize the test, has described a tiered interpretation:

• Optimal: below 3.7 µM
• Moderate risk: 3.7 to 6.2 µM
• High risk: above 6.2 µM

These thresholds are based on tertile distributions from cardiovascular outcome cohorts and should be interpreted alongside your full lipid panel, hsCRP, fasting glucose, blood pressure, and family history. A single TMAO number does not make or break a cardiovascular risk assessment.

Does Fasting Status Change the Result?

Yes, meaningfully. A meal rich in choline or carnitine can raise your TMAO transiently within two to four hours. Research by Zhu et al. showed that a single egg meal raised plasma TMAO in omnivores but not in vegans, because vegans lack the gut bacteria that produce TMA efficiently. A 12-hour fast standardizes the measurement, so always confirm your lab's collection instructions before your draw.

Lab-to-Lab Variability

TMAO assays are not yet standardized across clinical laboratories the way HbA1c is. Mass spectrometry-based platforms give the most reproducible results. If you are tracking TMAO over time, use the same laboratory for each draw. Comparing a value from one lab to a reference range from another lab is unreliable.

How to Interpret a High TMAO Result

A result above 6.2 µM in a fasting plasma sample is a signal worth taking seriously, but it is not a diagnosis on its own.

What High TMAO Tells You

High TMAO means one or more of the following is likely:

1. Your gut microbiome has a high TMA-producing capacity, driven by diet, antibiotic history, or underlying dysbiosis.
2. Your liver FMO3 enzyme is highly active, converting TMA to TMAO rapidly.
3. Your kidneys are not clearing TMAO efficiently. Renal impairment raises TMAO substantially, so women with chronic kidney disease (CKD) can have very high levels that reflect kidney function as much as cardiovascular risk.

A 2019 JAMA Cardiology analysis found that women in the top TMAO tertile had a significantly higher risk of incident heart failure compared with women in the lowest tertile (hazard ratio 1.35, 95% CI 1.14 to 1.60). Heart failure risk in women is often under-recognized, and TMAO may add incremental risk stratification beyond traditional markers.

Conditions That Can Drive High TMAO in Women

• PCOS: Gut dysbiosis is documented in PCOS, and a 2021 study in the Journal of Clinical Endocrinology and Metabolism found elevated TMAO in women with PCOS compared with controls, independent of BMI.
• Postmenopausal status: Estrogen loss reduces Lactobacillus diversity in the gut. Less microbial diversity can shift the microbiome toward higher TMA production.
• Obesity and metabolic syndrome: Both are associated with a less diverse gut microbiome and higher fasting TMAO.
• Chronic kidney disease: The kidneys clear TMAO. CKD stages 3 to 5 can raise TMAO dramatically.
• Hypothyroidism: Thyroid hormone influences gut motility and microbiome composition; untreated hypothyroidism may worsen dysbiosis and indirectly raise TMAO.

What High TMAO Does Not Mean

A high result does not mean you will have a heart attack. It is one risk marker among many. Women with very high TMAO but no other traditional risk factors are in a different position than women with high TMAO plus hypertension, diabetes, and a strong family history.

How to Interpret a Low TMAO Result

Low TMAO, generally below 3.7 µM in a fasting sample, typically indicates a gut microbiome with low TMA-producing capacity, a predominantly plant-based diet, or both.

When Low TMAO Is Reassuring

For most women, a low fasting TMAO is a favorable finding. Plant-based diets, which are rich in fiber and short-chain fatty acid production, tend to support Bifidobacterium and Lactobacillus species over TMA-producing bacteria. A study in the European Heart Journal confirmed that vegans and vegetarians have substantially lower plasma TMAO than omnivores eating equivalent caloric intakes.

When Low TMAO Does Not Rule Out Cardiovascular Risk

Low TMAO does not eliminate cardiovascular risk. A woman can have low TMAO and still have high LDL-C, lipoprotein(a), or hsCRP. TMAO adds information; it does not replace existing markers.

A very low TMAO in someone eating a high-meat diet might also reflect a genuinely low-TMA-producing microbiome, which is its own interesting finding but does not require clinical action unless other risk factors are present.

TMAO Across Life Stages

Understanding your TMAO result is more useful when you read it through the lens of your current hormonal and reproductive context. Here is how the marker behaves differently across the key life stages most relevant to WomanRx readers.

Reproductive Years (Ages Roughly 18 to 40)

During the years when your menstrual cycle is regular, estrogen and progesterone cycle every 28 days and influence gut motility, microbiome composition, and even FMO3 expression. Choline needs are higher during this life stage because choline supports cell membrane synthesis and is consumed rapidly by the liver during high-metabolic-demand phases. Eating more choline-rich foods to meet those needs may raise TMAO somewhat, particularly if your gut microbiome has high TMA-producing capacity. A moderately elevated TMAO in an otherwise healthy woman in her 30s with no other risk factors is less alarming than the same reading in a 58-year-old with hypertension.

Women with PCOS in this age group warrant particular attention. The combination of insulin resistance, androgen excess, and documented gut dysbiosis may keep TMAO elevated even without a high-meat diet, as the JCEM 2021 PCOS data showed.

Trying to Conceive and Pregnancy

Choline requirements increase substantially during pregnancy to support fetal brain development. The American Medical Association and the National Institutes of Health recommend 450 mg per day of choline during pregnancy, rising to 550 mg per day during lactation. This means pregnant women are often intentionally eating more eggs and dairy, both of which raise TMAO.

TMAO testing is not standard practice in pregnancy. There is no established guidance from ACOG on routine TMAO screening during prenatal care, and the clinical significance of elevated TMAO in pregnancy specifically has not been studied in large prospective trials. If your TMAO was elevated before pregnancy, discuss with your clinician whether repeat testing during pregnancy is warranted given your full cardiovascular risk profile.

Perimenopause

Perimenopause, roughly ages 40 to 52 for most women though the range is wide, is when the gut microbiome begins to shift in response to declining estrogen. A 2019 Cell Host and Microbe study showed that postmenopausal women had significantly less microbiome diversity than premenopausal women matched for BMI and diet. Less diversity correlates with higher TMA-producing bacterial populations in some individuals. If you are in perimenopause and your TMAO has risen compared with a prior result, declining estrogen may be a contributing factor worth discussing alongside menopausal hormone therapy (MHT) considerations.

The Menopause Society (formerly NAMS) does not currently list TMAO as a standard cardiovascular screening marker in their 2023 menopause hormone therapy position statement, but clinicians practicing integrative cardiovascular medicine in menopause increasingly include it in advanced lipid panels.

Postmenopause

This is the life stage where TMAO risk data are most strong. Most cardiovascular outcome studies include a large proportion of postmenopausal women, and the JAMA Cardiology heart failure risk data cited earlier are most directly applicable here. A postmenopausal woman with TMAO above 6.2 µM should have a full cardiovascular risk assessment including coronary artery calcium (CAC) scoring if not already done, discussion of statin therapy per ACC/AHA pooled cohort equation thresholds, and dietary modification.

How to Lower TMAO

Diet is the most evidence-supported lever for lowering TMAO. The gut microbiome changes in response to dietary shifts within days to weeks.

Dietary Changes With the Strongest Evidence

Reduce red meat and processed meat. Carnitine in red meat is a major TMA precursor. A controlled feeding study by Koeth et al. showed that a single 8-ounce sirloin steak raised plasma TMAO within hours in omnivores, and that chronic red meat eating increased the abundance of TMA-producing bacteria over time.

Shift toward a Mediterranean or plant-forward diet. The PREDIMED trial, which enrolled 7,447 adults at high cardiovascular risk, showed that a Mediterranean diet reduced MACE by approximately 30% compared with a low-fat control diet. While PREDIMED did not measure TMAO directly, subsequent mechanistic work has shown that Mediterranean-diet adherents have lower TMAO and more favorable gut microbiome composition.

Increase fiber intake. Dietary fiber feeds Bifidobacterium and Lactobacillus, which compete with TMA-producing organisms. Aim for 25 to 38 grams per day from whole foods, not supplements.

Consider fish thoughtfully. Fish is high in choline and can raise TMAO acutely. Paradoxically, populations with the highest fish intake (e.g., Japanese cohorts) do not always show the expected cardiovascular harm from high TMAO, possibly because omega-3 fatty acids and other fish constituents offset the risk. This area requires more research, and the data in women specifically are limited.

Interventions Under Investigation

Resveratrol and DMB (3,3-dimethyl-1-butanol). DMB is a TMA-lyase inhibitor that blocks bacterial TMA production without killing bacteria. Preclinical data from Wang et al. In Cell Metabolism showed DMB reduced TMAO and attenuated atherosclerosis in mice. Human trials are not yet complete, and DMB is not currently approved or commercially available as a supplement.

Probiotics. Specific probiotic strains may shift the microbiome away from TMA production, but a 2020 Cochrane-adjacent systematic review found inconsistent effects of probiotic supplementation on TMAO in humans. No single strain is currently recommended by guidelines for TMAO reduction.

Exercise. Regular aerobic exercise increases gut microbiome diversity. A 2019 study in Medicine and Science in Sports and Exercise found that eight weeks of aerobic training significantly increased Butyrivibrio and reduced TMA-producing species. This is a low-risk, broadly beneficial intervention with plausible TMAO-lowering effects.

Who Should Consider TMAO Testing

TMAO testing is not yet a standard first-line cardiovascular screening tool recommended by AHA, ACC, or USPSTF. It fits best as an advanced panel in specific clinical scenarios.

Consider TMAO testing if you:

• Have premature cardiovascular disease (defined as MACE before age 65 in women)
• Have elevated hsCRP or Lp(a) with otherwise normal LDL-C and want additional risk stratification
• Have PCOS with insulin resistance and no clear dietary explanation for metabolic dysregulation
• Are postmenopausal with an intermediate 10-year ASCVD risk (7.5% to 20%) and want to guide statin or lifestyle decisions
• Have unexplained gut dysbiosis symptoms alongside cardiovascular risk factors

TMAO testing is less useful if you:

• Already have a clear, high ASCVD risk profile where treatment decisions are already established
• Have stage 3 to 5 CKD (TMAO will be elevated due to impaired renal clearance, not diet or microbiome, and the result can mislead)
• Are younger than 30 with no cardiovascular risk factors

Pregnancy and Lactation Considerations

TMAO is a biomarker, not a drug. There is no pregnancy or lactation safety concern with measuring a blood level of TMAO. The clinical considerations in pregnancy and lactation relate to the dietary and supplement strategies used to modify TMAO, not the test itself.

Choline and TMAO in pregnancy. Because choline requirements rise in pregnancy and lactation, some increase in TMAO is expected in women eating adequate choline. This should not be a reason to restrict choline during pregnancy. Choline is critical for fetal neural tube closure and brain development. The NIH Office of Dietary Supplements confirms that choline deficiency in pregnancy is associated with neural tube defects and impaired fetal brain development.

Carnitine supplements. L-carnitine is sometimes marketed for postpartum energy or weight loss. Because carnitine is a direct TMAO precursor, women with high baseline TMAO should discuss carnitine supplementation with their clinician before using it during the postpartum period.

Probiotic use in pregnancy. Probiotics are generally considered safe in pregnancy per ACOG's summary of evidence, though specific strain safety data are limited. If a clinician recommends probiotics as part of a TMAO-lowering strategy and you are pregnant, confirm the specific strain safety profile with your OB or midwife.

Reading Your TMAO Result Alongside Other Labs

No cardiovascular risk marker is an island. When you receive your TMAO result, look at it next to:

• LDL-C and non-HDL-C: Standard lipid markers that TMAO complements but does not replace.
• hsCRP: An inflammation marker. High TMAO plus high hsCRP suggests both gut-mediated and inflammatory cardiovascular risk.
• Lp(a): Lipoprotein(a) is genetically determined and does not respond to diet or TMAO-lowering strategies. Knowing both helps separate genetic from microbiome-driven risk.
• Fasting glucose and HbA1c: Insulin resistance drives gut dysbiosis, which drives TMAO. High TMAO with high HbA1c points to a metabolic-gut axis that benefits from insulin-sensitizing diet and exercise.
• Thyroid function (TSH, free T4): Hypothyroidism slows gut motility and may worsen dysbiosis. A woman with high TMAO and unrecognized hypothyroidism may see TMAO fall after thyroid hormone optimization.

The American Heart Association's 2021 dietary guidance acknowledges TMAO as an emerging gut-microbiome-related cardiovascular risk marker, though it stops short of recommending routine clinical testing. The guidance is consistent with using dietary patterns to modify TMAO indirectly, even when TMAO is not measured directly.

As WomanRx clinician Elena Vasquez, MD, puts it: "TMAO is most useful not as a scare tactic but as a conversation starter. When a woman has a high result, it opens a discussion about her gut, her diet, her hormonal history, and her cardiovascular risk in a way that a cholesterol panel alone never does. That specificity is the point."